Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2023-08-24 Sale | 2023-08-28 4:20 pm | Enliven Therapeutics Inc. | ELVN | 5AM Partners VI LLC 5AM Ventures VI L.P. 5AM Opportunities I (GP) LLC 5AM Opportunities I L.P. PARMAR KUSH Schwab Andrew J. 10% Owner | 440,000 | $16 | $7,040,000 | 887,507 (Indirect) | View |
| 2023-02-23 Purchase | 2023-02-27 5:14 pm | Enliven Therapeutics Inc. | ELVN | COMMODORE CAPITAL LP 10% Owner | 622 | $22.07 | $13,723 | 2,178,531 (Indirect) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2023-05-17 Exercise | 2023-05-19 4:19 pm | N/A 2032-06-01 | Enliven Therapeutics Inc. | ELVN | ORBIMED ADVISORS LLC OrbiMed Capital GP VII LLC OrbiMed Genesis GP LLC Director 10% Owner | 2,125 | $0 | 8,951,463 (Indirect) | View |
| 2023-05-17 Exercise | 2023-05-19 4:19 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | ORBIMED ADVISORS LLC OrbiMed Capital GP VII LLC OrbiMed Genesis GP LLC Director 10% Owner | 2,125 | $4.28 | 8,951,463 (Indirect) | View |
| 2023-05-17 Exercise | 2023-05-19 4:12 pm | N/A 2032-06-01 | Enliven Therapeutics Inc. | ELVN | Gupta Rishi Director 10% Owner | 2,125 | $0 | 8,951,463 (Indirect) | View |
| 2023-05-17 Exercise | 2023-05-19 4:12 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Gupta Rishi Director 10% Owner | 2,125 | $4.28 | 8,951,463 (Indirect) | View |
| 2023-04-04 Option Award | 2023-04-06 8:34 pm | N/A 2033-04-04 | Enliven Therapeutics Inc. | ELVN | Patel Anish Chief Operating Officer | 206,000 | $0 | 206,000 (Direct) | View |
| 2023-04-04 Option Award | 2023-04-06 8:33 pm | N/A 2033-04-04 | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P Chief Scientific Officer | 206,000 | $0 | 206,000 (Direct) | View |
| 2023-04-04 Option Award | 2023-04-06 8:32 pm | N/A 2033-04-04 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin Chief Financial Officer | 206,000 | $0 | 206,000 (Direct) | View |
| 2023-04-04 Option Award | 2023-04-06 8:32 pm | N/A 2033-04-04 | Enliven Therapeutics Inc. | ELVN | Collins Helen Louise Chief Medical Officer | 206,000 | $0 | 206,000 (Direct) | View |
| 2023-04-04 Option Award | 2023-04-06 8:30 pm | N/A 2033-04-04 | Enliven Therapeutics Inc. | ELVN | Kintz Samuel President and CEO | 452,000 | $0 | 452,000 (Direct) | View |
| 2023-02-23 Option Award | 2023-04-06 8:22 pm | N/A 2033-02-23 | Enliven Therapeutics Inc. | ELVN | Schwab Andrew J. Director 10% Owner | 27,567 | $0 | 27,567 (Direct) | View |
| 2023-02-23 Option Award | 2023-04-06 8:20 pm | N/A 2033-02-23 | Enliven Therapeutics Inc. | ELVN | Phillips Andrew John Director | 27,567 | $0 | 27,567 (Direct) | View |
| 2023-02-23 Option Award | 2023-04-06 8:19 pm | N/A 2033-02-23 | Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director | 34,458 | $0 | 34,458 (Direct) | View |
| 2023-02-23 Option Award | 2023-04-06 8:18 pm | N/A 2033-02-23 | Enliven Therapeutics Inc. | ELVN | Gupta Rishi Director 10% Owner | 27,567 | $0 | 27,567 (Direct) | View |
| 2023-02-23 Option Award | 2023-04-06 8:17 pm | N/A 2033-02-23 | Enliven Therapeutics Inc. | ELVN | Derynck Mika K Director | 27,567 | $0 | 27,567 (Direct) | View |
| 2023-02-23 Option Award | 2023-04-06 8:16 pm | N/A 2033-02-23 | Enliven Therapeutics Inc. | ELVN | Bauer Jake Director | 27,567 | $0 | 27,567 (Direct) | View |
| 2023-02-23 Option Award | 2023-04-06 8:15 pm | N/A 2033-02-23 | Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director | 27,567 | $0 | 27,567 (Direct) | View |
Ownership | 2023-03-06 5:18 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | 5AM Partners VI LLC 5AM Ventures VI L.P. 5AM Opportunities I (GP) LLC 5AM Opportunities I L.P. PARMAR KUSH 10% Owner | 0 | $0 | 5,798,475 (Indirect) | View |
| 2023-02-23 Option Award | 2023-02-27 9:55 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Schwab Andrew J. Director | 5,798,475 | $0 | 960,383 (Indirect) | View |
| 2023-02-23 Option Award | 2023-02-27 9:54 pm | N/A 2032-08-12 | Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director | 239,056 | $0 | 201,649 (Direct) | View |
| 2023-02-23 Option Award | 2023-02-27 9:53 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Gupta Rishi Director 10% Owner | 7,899,572 | $0 | 288,114 (Indirect) | View |
| 2023-02-23 Option Award | 2023-02-27 9:51 pm | N/A 2032-08-12 | Enliven Therapeutics Inc. | ELVN | Bauer Jake Director | 105,078 | $0 | 105,078 (Direct) | View |
| 2023-02-23 Option Award | 2023-02-27 9:43 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Derynck Mika K Director | 87,373 | $0 | 87,373 (Direct) | View |
| 2023-02-23 Option Award | 2023-02-27 9:35 pm | N/A 2030-06-15 | Enliven Therapeutics Inc. | ELVN | Patel Anish Chief Operating Officer | 519,963 | $0 | 519,963 (Direct) | View |
| 2023-02-23 Option Award | 2023-02-27 9:34 pm | N/A 2030-06-15 | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P Chief Scientific Officer | 1,550,116 | $0 | 1,550,116 (Direct) | View |
| 2023-02-23 Option Award | 2023-02-27 9:33 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin Chief Financial Officer | 262,120 | $0 | 262,120 (Direct) | View |
| 2023-02-23 Option Award | 2023-02-27 9:33 pm | N/A 2030-06-15 | Enliven Therapeutics Inc. | ELVN | Kintz Samuel President and CEO | 1,924,969 | $0 | 837,444 (Direct) | View |
| 2023-02-23 Option Award | 2023-02-27 9:32 pm | N/A 2031-06-17 | Enliven Therapeutics Inc. | ELVN | Collins Helen Louise Chief Medical Officer | 287,084 | $0 | 287,084 (Direct) | View |
| 2023-02-23 Option Award | 2023-02-27 8:30 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | ORBIMED ADVISORS LLC OrbiMed Capital GP VII LLC OrbiMed Genesis GP LLC Director 10% Owner | 7,899,572 | $0 | 288,114 (Indirect) | View |
| 2023-02-23 Other | 2023-02-27 5:14 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | COMMODORE CAPITAL LP 10% Owner | 729,891 | $0 | 2,178,531 (Indirect) | View |